Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Using The Molecular Classification Of Glioblastoma To Inform Personalized Treatment
Adriana Olar, K. Aldape
Published 2014 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Glioblastoma is the most common and most aggressive diffuse glioma, associated with short survival and uniformly fatal outcome, irrespective of treatment. It is characterized by morphological, genetic and gene‐expression heterogeneity. The current standard of treatment is maximal surgical resection, followed by radiation, with concurrent and adjuvant chemotherapy. Due to the heterogeneity, most tumours develop resistance to treatment and shortly recur. Following recurrence, glioblastoma is quickly fatal in the majority of cases. Recent genetic molecular advances have contributed to a better understanding of glioblastoma pathophysiology and disease stratification. In this paper we review basic glioblastoma pathophysiology, with emphasis on clinically relevant genetic molecular alterations and potential targets for further drug development. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
This paper references
Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age
S. Ha (2013)
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
M. Sanson (2009)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
H. Ohgaki (2005)
Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
C. Franco-Hernández (2009)
Deadly teamwork: neural cancer stem cells and the tumor microenvironment.
J. Lathia (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
C. Hartmann (2010)
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial
Maria Teresa Solomón (2012)
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
J. Uhm (2011)
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
D. Beier (2011)
Prognostic impact of molecular markers in a series of 220 primary glioblastomas
C. Houillier (2006)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
S. Nobusawa (2009)
The transcriptional network for mesenchymal transformation of brain tumours
J. Uhm (2010)
Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells.
A. Vollmann (2006)
Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma
V. Sharma (2010)
p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
Y. T. Yeung (2012)
Identification of a cancer stem cell in human brain tumors.
S. Singh (2003)
A. Mantovani (2008)
WHO Classification of Tumors of the Central Nervous System
DN Louis (2007)
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
J. Smith (2001)
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.
T. A. Dolecek (2012)
Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation
S. Takano (2011)
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
A. Brandes (2010)
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
G. Liu (2006)
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Yasushi Soda (2011)
Glioblastoma stem-like cells give rise to tumour endothelium
Rong Wang (2010)
Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma
T. Batchelor (2004)
Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients
M. Bieńkowski (2013)
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
H. Friedman (2009)
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing
J. Felsberg (2010)
Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways
Tao Lu (2007)
'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis
Yuan Rong (2006)
Glioblastoma with Oligodendroglioma Component (GBM‐O): Molecular Genetic and Clinical Characteristics
C. Appin (2013)
Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features
R. Benito (2010)
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
R. Galli (2004)
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
P. Brown (2008)
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
S. Yip (2012)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller (2010)
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
A. Lai (2011)
Genetic pathways to primary and secondary glioblastoma.
H. Ohgaki (2007)
MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
B. Kaina (2007)
S. Bruce (2001)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
J. Raizer (2010)
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
R. Verhaak (2010)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
M. Hegi (2011)
MGMT gene silencing and benefit from temozolomide in glioblastoma.
M. Hegi (2005)
Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer
T. Nakagawachi (2003)
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Parsons (2008)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
R. Stupp (2005)
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
C. Horbinski (2009)
Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified.
L. Liu (1998)
Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker *
M. Preusser (2008)
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
L. Ricci‐Vitiani (2011)
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.
A. Ekstrand (1991)
ErbB receptors: from oncogenes to targeted cancer therapies.
H. Zhang (2007)
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
R. Nishikawa (1994)
Molecular pathogenesis of IDH mutations in gliomas
K. Ichimura (2012)
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
K. Bhat (2011)
Genetic pathways to glioblastoma: a population-based study
H Ohgaki (2004)
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Adriana Olar (2012)
Phase III Trial of bevacizumab added to standard radiotherapy and temozolomide for newlydiagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in Avaglio
O Chinot (2012)
Clinical Practice Guidelines in Oncology
N. NCC (2013)
A restricted cell population propagates glioblastoma growth after chemotherapy
J. Chen (2012)
Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.
M. Nakamura (2001)
Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis
R. Olson (2011)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
R. McLendon (2008)
Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.
N. Sugawa (1990)
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
R. Bonavia (2012)
Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas
Jonathan Hobbs (2012)
Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome
G. Kaloshi (2011)
Neural Stem/Progenitors and Glioma Stem-Like Cells Have Differential Sensitivity to Chemotherapy
M. Chamberlain (2011)
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
M. J. van den Bent (2009)
Genetic profile of astrocytic and oligodendroglial gliomas
H. Ohgaki (2011)
Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
J. Xiong (2010)
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
A. Fabi (2009)
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.
J. Forsythe (1996)
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
B. J. Scott (2010)
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
B. S. Zhou (2009)
Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
B. Ellezam (2012)
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
M. Jansen (2010)
Interleukins in glioblastoma pathophysiology: implications for therapy
Y. T. Yeung (2013)
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.
K. Bhat (2013)
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
W. Wick (2009)
Molecular subclassification of diffuse gliomas: Seeing order in the chaos
J. Huse (2011)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
M. J. van den Bent (2010)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
D. Rohle (2013)
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
R. Stupp (2009)
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
N. Shinojima (2003)
The 2007 WHO Classification of Tumours of the Central Nervous System
D. N. Louis (2007)
The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years
A. Korshunov (2005)
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
L. Frederick (2000)
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
R. Pallini (2008)
The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.
L. Cooper (2012)
Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells*
A. Soeda (2008)
Bevacizumab in recurrent high-grade pediatric gliomas.
A. Narayana (2010)
Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.
J. Rak (2006)
Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population
D. Brat (2004)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
J. D. de Groot (2010)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
G. Reifenberger (2012)
Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
J. Lathia (2011)
IDH1 and IDH2 mutations in gliomas.
F. Ducray (2009)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
M. Hegi (2011)
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Barbara S. Paugh (2010)
MGMT gene promoter methylation in pediatric glioblastomas
Arti Srivastava (2010)
Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome.
Y. Wang (2012)
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M. Labussière (2010)
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma
A. Donson (2007)
Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
M. Simmons (2001)
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
M. Weller (2009)
IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group
I. Pollack (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
A. Rivera (2010)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
A. Brandes (2008)
Analysis of the IDH1 codon 132 mutation in brain tumors
J. Balss (2008)
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
Yuan Rong (2005)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh (2012)
IL-6 gene amplification and expression in human glioblastomas
A. Tchirkov (2001)
A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
M. J. van den Bent (2011)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
H. Phillips (2006)
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Y. Jiao (2012)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
K. Ichimura (2009)
MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma
F. Rodriguez (2008)
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Y. Sonoda (2009)
The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas
L. Cooper (2010)
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
María-del-Mar Inda (2010)
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide
M. Hegi (2004)
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
M. Zöller (2011)
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
M. Feldkamp (1999)
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
M. Mrugala (2009)
Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival
M. Eoli (2007)
Identification of human brain tumour initiating cells
S. Singh (2004)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
C. Hartmann (2009)
Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
G. Cairncross (2008)
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors
P. Mur (2013)
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
J. Felsberg (2011)
EGFR gene amplification ‐ rearrangement in human glioblastomas
K. Schwechheimer (1995)
Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro
T. Ignatova (2002)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
S. Bao (2006)
Expression of EGFRvIII in glioblastoma: prognostic significance revisited.
N. Montano (2011)
Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification
B. Klink (2011)
O6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment
Prerana Jha (2010)
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
H. Noushmehr (2010)
The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma
F. Ohka (2011)
Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling
Benedikte Hasselbalch (2010)
Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
Y. Piao (2013)
Studying a complex tumor: potential and pitfalls.
S. Zheng (2012)
Interleukin-6 gene amplification and shortened survival in glioblastoma patients
A. Tchirkov (2007)
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
M. Mellai (2011)
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
L. C. Hygino da Cruz (2011)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
J. Uhm (2012)
Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model
H. Armah (2010)
This paper is referenced by
Glutamine uptake and utilization of human mesenchymal glioblastoma in orthotopic mouse model
Kristell Oizel (2020)
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Qianghu Wang (2017)
Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma
A. Arbab (2017)
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.
K. Vigneswaran (2015)
System-based approaches as prognostic tools for glioblastoma
M. Salvucci (2019)
Jing-Nan Hu (2013)
Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas
J. Kosty (2017)
Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the SGK1 Gene Are Associated with Poorer Survival
S. Lehrer (2018)
Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells
C. Biray Avci (2015)
Nanoparticle based strategies for the treatment of Glioblastoma
F. Fisusi (2014)
EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas
N. Pérez-Janices (2015)
Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
H. Haynes (2014)
Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.
A. Barrette (2018)
Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.
A. Shankar (2016)
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.
R. An (2019)
Genomics of brain tumor imaging.
W. Pope (2015)
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord
Yuxuan Wang (2015)
Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
S. Mukherjee (2019)
Functional analysis of cancer gene subtype from co-clustering and classification
Logenthiran Machap (2020)
The 18-kDa mitochondrial translocator protein in gliomas: from the bench to bedside.
K. Janczar (2015)
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial
Lin Kong (2019)
A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.
A. Griveau (2018)
Reconstructing the molecular life history of gliomas
F. Barthel (2018)
Impact of anesthesia and analgesia techniques on glioblastoma progression. A narrative review
Ann Privorotskiy (2020)
Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment
Qianghu Wang (2016)
Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.
S. Daniele (2017)
LncRNA‐XIST/microRNA‐126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma
Zhihua Cheng (2019)
Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway
Yujiang Peng (2018)
ALG2 regulates glioblastoma cell proliferation, migration and tumorigenicity.
Dunke Zhang (2017)
Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers
Ádám Nagy (2017)
Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
A. Kanner (2014)
Epstein–Barr Virus in Gliomas: Cause, Association, or Artifact?
S. Akhtar (2018)See more